This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Acipimox is a niacin derivative used as a hypolipidemic agent. It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid. Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use. Adverse effects include flushing (associated with Prostaglandin D2), palpitations, and GI disturbances. Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox. High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout.
|External IDs||Not Available|
|Product Ingredients||Not Available|
|Brand mixtures||Not Available|
|Weight||Average: 154.125 |
Used in the treatment of hyperlipidemias (abnormally elevated levels of any or all lipids and/or lipoproteins in the blood).
|Structured Indications||Not Available|
|Mechanism of action|
Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL.
|Volume of distribution||Not Available|
|Protein binding||Not Available|
|Route of elimination||Not Available|
|Half life||Not Available|
|Affected organisms||Not Available|
|Pharmacogenomic Effects/ADRs||Not Available|
|Food Interactions||Not Available|
|Synthesis Reference||Not Available|
|General References||Not Available|
|ATC Codes||C10AD06 — Acipimox|
|AHFS Codes||Not Available|
|PDB Entries||Not Available|
|FDA label||Not Available|
|Experimental Properties||Not Available|
|Predicted ADMET features||Not Available|
|Mass Spec (NIST)||Not Available|
|Description||This compound belongs to the class of organic compounds known as pyrazine carboxylic acids. These are heterocyclic compounds containing a pyrazine ring substituted by one or more carboxylic acid groups.|
|Super Class||Organoheterocyclic compounds|
|Direct Parent||Pyrazine carboxylic acids|
|Alternative Parents||Pyrazinium compounds / Vinylogous amides / Heteroaromatic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic zwitterions / Organic oxides / Hydrocarbon derivatives|
|Substituents||Pyrazine carboxylic acid / Pyrazinium / Heteroaromatic compound / Vinylogous amide / Carboxylic acid derivative / Carboxylic acid / Monocarboxylic acid or derivatives / Azacycle / Organic nitrogen compound / Organic zwitterion/ Hydrocarbon derivative / Organic oxide / Organooxygen compound / Organonitrogen compound / Organopnictogen compound / Organic oxygen compound / Aromatic heteromonocyclic compound|
|Molecular Framework||Aromatic heteromonocyclic compounds|
|External Descriptors||Not Available|